{"id":72452,"date":"2026-08-13T17:43:10","date_gmt":"2026-08-13T09:43:10","guid":{"rendered":"https:\/\/flcube.com\/?p=72452"},"modified":"2026-08-13T17:43:11","modified_gmt":"2026-08-13T09:43:11","slug":"ark-biopharmaceuticals-first-in-class-afc-ak0406-wins-nmpa-approval-for-influenza-prevention-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72452","title":{"rendered":"Ark Biopharmaceutical&#8217;s First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Ark Biopharmaceutical Co., Ltd.<\/strong> announced that its independently developed <strong>first-in-class long-acting antiviral drug-Fc conjugate (AFC) AK0406 injection<\/strong> has received approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> to conduct <strong>clinical trials for influenza prevention<\/strong>, moving the candidate into Chinese clinical development on the back of a fully dosed Phase 1 study in Australia.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai Ark Biopharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>AK0406 injection \u2014 first-in-class long-acting antiviral drug-Fc conjugate (AFC)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Influenza prevention<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>13 Aug 2026<\/td><\/tr><tr><td><strong>Prior Milestone<\/strong><\/td><td>Australian HREC approval for Phase 1 trials (Feb 2026)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-ak0406\" class=\"wp-block-heading\">Drug Profile \u2013 AK0406<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Modality:<\/strong> Innovative <strong>long-acting antiviral drug-Fc conjugate (AFC)<\/strong>, independently developed by Ark Biopharmaceutical \u2014 precisely conjugating a highly potent antiviral small molecule with an <strong>antibody Fc fragment<\/strong> for extended circulation<\/li>\n\n\n\n<li><strong>Application Scope:<\/strong> Long-acting <strong>pre- or post-exposure prophylaxis<\/strong> and potential <strong>therapeutic applications<\/strong> for influenza<\/li>\n\n\n\n<li><strong>Target Need:<\/strong> Addresses clinical prevention needs during <strong>peak influenza seasons<\/strong>, where vaccines and short-acting antivirals leave coverage gaps<\/li>\n\n\n\n<li><strong>Preclinical Profile:<\/strong> <strong>Broad-spectrum, highly potent, and long-acting<\/strong> antiviral properties, with comprehensive optimization across <strong>structural design, antiviral activity, pharmacokinetics, and manufacturing<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-progress\" class=\"wp-block-heading\">Clinical Progress<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Program<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Australia Phase 1<\/strong><\/td><td>HREC approval Feb 2026; <strong>enrollment and dosing of all healthy-adult cohorts completed<\/strong>; currently in follow-up stage<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>NMPA clinical trial approval granted 13 Aug 2026; trial initiation expected<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-in-Class Modality:<\/strong> The AFC architecture \u2014 extending small-molecule antivirals via Fc fusion \u2014 offers a differentiated approach in influenza prophylaxis, distinct from both seasonal vaccines and conventional antivirals.<\/li>\n\n\n\n<li><strong>Prophylaxis Opportunity:<\/strong> A long-acting preventive could serve populations poorly covered by vaccination \u2014 the elderly, immunocompromised, and frontline healthcare workers during seasonal peaks.<\/li>\n\n\n\n<li><strong>Parallel Development Tracks:<\/strong> With the Australian Phase 1 fully dosed and NMPA clearance secured, Ark Biopharmaceutical can pursue synchronized US-APAC-China development, strengthening its clinical dataset and partnering appeal.<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Follow-up results from the Australian cohorts and China trial design details were not disclosed.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the clinical development and commercial potential of AK0406. Actual results may differ due to risks including clinical progress, safety outcomes, regulatory timelines, and competitive dynamics in influenza prevention.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Ark Biopharmaceutical Co., Ltd. announced that its independently developed first-in-class long-acting antiviral drug-Fc conjugate&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[1443,62],"class_list":["post-72452","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-ark-biopharmaceutical","tag-clinical-trial-approval-initiation"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ark Biopharmaceutical&#039;s First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Ark Biopharmaceutical Co., Ltd. announced that its independently developed first-in-class long-acting antiviral drug-Fc conjugate (AFC) AK0406 injection has received approval from China&#039;s National Medical Products Administration (NMPA) to conduct clinical trials for influenza prevention, moving the candidate into Chinese clinical development on the back of a fully dosed Phase 1 study in Australia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72452\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ark Biopharmaceutical&#039;s First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"Shanghai Ark Biopharmaceutical Co., Ltd. announced that its independently developed first-in-class long-acting antiviral drug-Fc conjugate (AFC) AK0406 injection has received approval from China&#039;s National Medical Products Administration (NMPA) to conduct clinical trials for influenza prevention, moving the candidate into Chinese clinical development on the back of a fully dosed Phase 1 study in Australia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72452\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-13T09:43:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-13T09:43:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72452#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72452\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ark Biopharmaceutical&#8217;s First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials\",\"datePublished\":\"2026-08-13T09:43:10+00:00\",\"dateModified\":\"2026-08-13T09:43:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72452\"},\"wordCount\":359,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ark Biopharmaceutical\",\"Clinical trial approval \\\/ initiation\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72452#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72452\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72452\",\"name\":\"Ark Biopharmaceutical's First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-13T09:43:10+00:00\",\"dateModified\":\"2026-08-13T09:43:11+00:00\",\"description\":\"Shanghai Ark Biopharmaceutical Co., Ltd. announced that its independently developed first-in-class long-acting antiviral drug-Fc conjugate (AFC) AK0406 injection has received approval from China's National Medical Products Administration (NMPA) to conduct clinical trials for influenza prevention, moving the candidate into Chinese clinical development on the back of a fully dosed Phase 1 study in Australia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72452#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72452\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72452#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ark Biopharmaceutical&#8217;s First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ark Biopharmaceutical's First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Ark Biopharmaceutical Co., Ltd. announced that its independently developed first-in-class long-acting antiviral drug-Fc conjugate (AFC) AK0406 injection has received approval from China's National Medical Products Administration (NMPA) to conduct clinical trials for influenza prevention, moving the candidate into Chinese clinical development on the back of a fully dosed Phase 1 study in Australia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72452","og_locale":"en_US","og_type":"article","og_title":"Ark Biopharmaceutical's First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials","og_description":"Shanghai Ark Biopharmaceutical Co., Ltd. announced that its independently developed first-in-class long-acting antiviral drug-Fc conjugate (AFC) AK0406 injection has received approval from China's National Medical Products Administration (NMPA) to conduct clinical trials for influenza prevention, moving the candidate into Chinese clinical development on the back of a fully dosed Phase 1 study in Australia.","og_url":"https:\/\/flcube.com\/?p=72452","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-13T09:43:10+00:00","article_modified_time":"2026-08-13T09:43:11+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72452#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72452"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ark Biopharmaceutical&#8217;s First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials","datePublished":"2026-08-13T09:43:10+00:00","dateModified":"2026-08-13T09:43:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72452"},"wordCount":359,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ark Biopharmaceutical","Clinical trial approval \/ initiation"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72452#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72452","url":"https:\/\/flcube.com\/?p=72452","name":"Ark Biopharmaceutical's First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-13T09:43:10+00:00","dateModified":"2026-08-13T09:43:11+00:00","description":"Shanghai Ark Biopharmaceutical Co., Ltd. announced that its independently developed first-in-class long-acting antiviral drug-Fc conjugate (AFC) AK0406 injection has received approval from China's National Medical Products Administration (NMPA) to conduct clinical trials for influenza prevention, moving the candidate into Chinese clinical development on the back of a fully dosed Phase 1 study in Australia.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72452#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72452"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72452#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ark Biopharmaceutical&#8217;s First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72452"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72452\/revisions"}],"predecessor-version":[{"id":72453,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72452\/revisions\/72453"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}